Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

Abstract This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal obser...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ji Eun Park, Young‐Ran Yoon, Chang Ho Kim, Jaehee Lee
Formato: Artigo
Idioma:Inglês
Publicado: Wiley 2022-04-01
Series:Thoracic Cancer
Assuntos:
alectinib
ALK rearrangement
lung cancer
M4
pharmacokinetics
Acceso en liña:https://doi.org/10.1111/1759-7714.14357
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares